Roche share price hasn’t exceeded the 20% return since the first swine flu symptoms were reported in Mexico in April 2009, a clear indication that Tamiflu is not the solution to the swine flu pandemic. Relenza, produced by GlaxoSmithKline, is also reporting the same ineffective results primarily over children under 12.